Get the Stockscreener App
3.65
13.00%
0.42
Immunitybio Inc stock is traded at $3.65, with a volume of 3.07M.
It is up +13.00% in the last 24 hours and up +0.83% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
See More
Previous Close:
$3.23
Open:
$3.2
24h Volume:
3.07M
Relative Volume:
1.13
Market Cap:
$2.54B
Revenue:
$302.00K
Net Income/Loss:
$-600.96M
P/E Ratio:
-3.2018
EPS:
-1.14
Net Cash Flow:
$-412.85M
1W Performance:
+6.41%
1M Performance:
+0.83%
6M Performance:
-39.77%
1Y Performance:
+168.38%
1-Day Range:
$3.1939
$3.72
1-Week Range:
$3.1939
$3.72
52-Week Range:
$1.25
$10.53
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
ImmunityBio (NASDAQ:IBRX) Trading Up 6.2%Time to Buy? - MarketBeat
IMMUNITYBIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ImmunityBio, Inc.IBRX - PR Newswire
ImmunityBio (NASDAQ:IBRX) Trading Down 4.5%Time to Sell? - MarketBeat
ImmunityBio Stock: Moving The Needle (NASDAQ:IBRX) - Seeking Alpha
More Layoffs From ImmunityBio, Bringing California’s Fall Cuts to 31 - BioSpace
Profund Advisors LLC Sells 121,163 Shares of ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World
Blair William & Co. IL Sells 106,742 Shares of ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World
Rhumbline Advisers Has $1.34 Million Stake in ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World
ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio (NASDAQ:IBRX) Shares Down 3.2% - MarketBeat
Bank of New York Mellon Corp Acquires 170,742 Shares of ImmunityBio, Inc. (NASDAQ:IBRX) - MarketBeat
Immunitybio Inc. (IBRX): Fast-Growing Penny Stock To Consider - Insider Monkey
Immunitybio Inc. (IBRX): Fast-Growing Penny Stock To Consider - Yahoo Finance
18,704 Shares in ImmunityBio, Inc. (NASDAQ:IBRX) Purchased by CIBC Asset Management Inc - Defense World
ImmunityBio reports extended survival in NSCLC therapy trial By Investing.com - Investing.com Australia
ImmunityBio reports extended survival in NSCLC therapy trial - Investing.com India
ImmunityBio (NASDAQ:IBRX) Trading 6.8% Higher - MarketBeat
ImmunityBio reports extended survival in NSCLC therapy trial - Investing.com
ImmunityBio reports extended survival in NSCLC therapy trial By Investing.com - Investing.com Canada
ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer - Business Wire
Analysts Predict Strong Growth for Cancer Vaccine Market: Key Biotech Stocks to Consider - Baystreet.ca
ImmunityBio lays off workers in Louisville - BizWest
Amid Major Threats, Merck Stock Is A Sell (NYSE:MRK) - Seeking Alpha
ImmunityBio, Inc. (NASDAQ:IBRX) Sees Significant Increase in Short Interest - MarketBeat
ImmunityBio (NASDAQ:IBRX) Stock Price Up 3.7% - MarketBeat
CG Oncology: Promising Data, But Looks Expensive (NASDAQ:CGON) - Seeking Alpha
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - GlobeNewswire Inc.
ImmunityBio (NASDAQ:IBRX) Trading 7.8% Higher - MarketBeat
ImmunityBio (NASDAQ:IBRX) Trading Down 6% Following Analyst Downgrade - Defense World
Piper Sandler Lowers ImmunityBio (NASDAQ:IBRX) Price Target to $4.75 - MarketBeat
ImmunityBio (NASDAQ:IBRX) Stock Price Down 6% - MarketBeat
ImmunityBio's Anktiva: Promising, But Organizational Complexity Keeps Me Cautious (IBRX) - Seeking Alpha
ImmunityBio (NASDAQ:IBRX) Shares Gap Down to $3.88 - Defense World
Aptose Biosciences (NASDAQ:APTO) vs. ImmunityBio (NASDAQ:IBRX) Critical Review - Defense World
ImmunityBio (NASDAQ:IBRX) Shares Gap Down to $3.88 - MarketBeat
California State Teachers Retirement System Reduces Holdings in ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World
Analyzing ImmunityBio (NASDAQ:IBRX) and Ginkgo Bioworks (NYSE:DNA) - Defense World
ImmunityBio: Anktiva's Launch ProgressesBladder Cancer Drug May Be 'Real Deal' - Seeking Alpha
ImmunityBio Second Quarter 2024 Earnings: Misses Expectations - Simply Wall St
ImmunityBio (NASDAQ:IBRX) Shares Down 2.7% on Disappointing Earnings - Defense World
Price T Rowe Associates Inc. MD Boosts Stock Holdings in ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World
Simplicity Wealth LLC Has $100,000 Position in ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World
ImmunityBio (NASDAQ:IBRX) Shares Down 2.7% Following Weak Earnings - MarketBeat
ImmunityBio: Q2 Earnings Snapshot - San Antonio Express-News
More Bladder Cancer Patients Can Access Innovative Therapy - Precision Vaccinations
ImmunityBio: Q2 Earnings Snapshot - The Washington Post
IBRX Stock Earnings: ImmunityBio Misses EPS, Misses Revenue for Q2 2024 - InvestorPlace
ImmunityBio: Q2 Earnings Snapshot - San Francisco Chronicle
ImmunityBio (IBRX) Reports Q2 Loss, Lags Revenue Estimates - MSN
ImmunityBio (IBRX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval - StockTitan
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.76%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):